Gilboa Therapeutics

📍 Rehovot, United States🗓 Founded 2020👥 9 employees💰 Last funded Jan 2021
Biotechnology Research🌐 gilboa.bio
Website LinkedIn
Gilboa Therapeutics is a preclinical-stage, cancer immunotherapy company focused on the development of next-generation cell therapies designed to harness the power of a patients own immune system to treat a wide range of cancers, with a mission to dramatically improve outcomes and save lives. SolidT cell therapy is based upon T cells that are genetically engineered to express a modified, high-affinity antibody receptor. This antibody receptor allows the engineered T cells to target antibody coated tumor cells. SolidT cells are designed to deliver a highly specific and potent attack that has demonstrated complete eradication of tumors in animal models, while leaving healthy tissue unharmed. SolidT is an innovative platform technology that has the potential to benefit patients with a range of both solid and hematological tumors, with an improved safety profile compared to other cell therapy approaches.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Gilboa Therapeutics?
Gilboa Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Gilboa Therapeutics last raise funding?
The most recent investment in Gilboa Therapeutics recorded on gritt.io was in January 2021.
When was Gilboa Therapeutics founded?
Gilboa Therapeutics was founded in 2020.
What industry is Gilboa Therapeutics in?
Gilboa Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Gilboa Therapeutics based?
Gilboa Therapeutics is headquartered in Rehovot, United States.